Alzheimer's Disease News and Research

RSS
Alzheimer's disease (AD) is an irreversible, progressive brain disease that slowly destroys memory and thinking skills and, eventually, the ability to carry out the simplest tasks of daily living. In most people with AD, symptoms first appear after age 60. AD is the most common cause of dementia among older people, but it is not a normal part of aging. Dementia refers to a decline in cognitive function that interferes with daily life and activities. AD starts in a region of the brain that affects recent memory, then gradually spreads to other parts of the brain. Although treatment can slow the progression of AD and help manage its symptoms in some people, currently there is no cure for this devastating disease.
Problems of unrecognized alcohol misuse among the elderly

Problems of unrecognized alcohol misuse among the elderly

State roundup: Indiana's effort to privatize public assistance

State roundup: Indiana's effort to privatize public assistance

Omeros identifies compounds that interact with orphan GPCRs associated with leukemia

Omeros identifies compounds that interact with orphan GPCRs associated with leukemia

EnVivo initiates EVP-0962 GSM Phase 1 clinical trial for Alzheimer’s disease

EnVivo initiates EVP-0962 GSM Phase 1 clinical trial for Alzheimer’s disease

First Edition: June 27, 2011

First Edition: June 27, 2011

Experts discuss global threat of Alzheimer's disease at House subcommittee hearing

Experts discuss global threat of Alzheimer's disease at House subcommittee hearing

Viewpoints: Sebelius defends IPAB; Wash Post on debt talks and entitlements

Viewpoints: Sebelius defends IPAB; Wash Post on debt talks and entitlements

Scientists gain insight into how brains process memory and sense of orientation

Scientists gain insight into how brains process memory and sense of orientation

Combined pediatric neuroscience programs at Barrow Neurological Institute

Combined pediatric neuroscience programs at Barrow Neurological Institute

Research offers avenue for creating Alzheimer's and HIV therapeutics

Research offers avenue for creating Alzheimer's and HIV therapeutics

Lithium can prevent aggregation of toxic proteins and cell loss linked with Parkinson's

Lithium can prevent aggregation of toxic proteins and cell loss linked with Parkinson's

Anticholinergic drugs might increase risk of cognitive impairment, death in older people

Anticholinergic drugs might increase risk of cognitive impairment, death in older people

Adeona enters agreement to begin proprietary zinc-based therapy Phase IIb trial in ALS

Adeona enters agreement to begin proprietary zinc-based therapy Phase IIb trial in ALS

Some drug mixtures may be fatal for elderly: study

Some drug mixtures may be fatal for elderly: study

New sAPPβ biomarker may identify people at risk of developing Alzheimer's

New sAPPβ biomarker may identify people at risk of developing Alzheimer's

Unraveling molecular dysfunction due to environmental toxin exposure

Unraveling molecular dysfunction due to environmental toxin exposure

New surprising details about flow of neurotransmitters between brain neurons

New surprising details about flow of neurotransmitters between brain neurons

Axxam receives ADDF grant to develop new therapeutics for Alzheimer's

Axxam receives ADDF grant to develop new therapeutics for Alzheimer's

Singer Glen Campbell diagnosed with Alzheimer’s

Singer Glen Campbell diagnosed with Alzheimer’s

Scientists observe key aspects of how memory circuits in the brain refine themselves

Scientists observe key aspects of how memory circuits in the brain refine themselves

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.